GlassScriptPhysician profile
Lawrence Price
NPI 1558336172
$5,700.48
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,984 · 2020: $675 · 2021: $499 · 2022: $373 · 2023: $1,075 · 2024: $93.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,168.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $680.02 | 2019-2021 | |
| Novo Nordisk INC | $556.42 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $439.75 | 2019-2024 | Mounjaro, Jardiance |
| Amgen INC. | $355.58 | 2019-2023 | Repatha, Otezla |
| Abbvie INC. | $339.16 | 2019-2023 | |
| Amarin Pharma, INC. | $326.51 | 2019-2020 | |
| Pfizer INC. | $311.36 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $293.19 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $266.94 | 2019-2020 | |
| Esperion Therapeutics, INC. | $254.36 | 2020-2023 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $217.65 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $164.68 | 2023 | |
| Astellas Pharma US INC | $153.42 | 2019-2023 | Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.24 | 2019-2023 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $151.13 | 2021 |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.